Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents.
The North American pediatric cooperative groups have performed a series of clinical …

Targeted therapies require cellular protein expression that meets specific requirements that
will maximize effectiveness, minimize off-target toxicities, and provide an opportunity for a …

Importance Chimeric and murine anti-G D2 antibodies are active against neuroblastoma,
but the development of neutralizing antibodies can compromise efficacy. To decrease …

Simple Summary Despite being in use for almost 50 years, monoclonal antibodies face
limitations in their implementation in clinical practice, particularly in pediatrics and pediatric …

The ALK F1174L mutation is associated with intrinsic and acquired resistance to crizotinib
and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model …

Sotos syndrome is an autosomal dominant condition characterized by overgrowth resulting
in tall stature and macrocephaly, together with an increased risk of tumorigenesis. The …

Background The 5-year survival rate for individuals with neuroblastoma is approaching 70%.
Few data exist, however, on the long-term outcomes of these patients, who are often …

Monoclonal antibodies (mAB) with tumor specificity are able to enhance the immunological
specificity of interleukin 2 (IL-2)-activated lymphokine activated killer (LAK) cells. Antibodies …

Neuroblastoma is remarkable for its clinical heterogeneity and is characterized by genomic
alterations that are strongly correlated with tumor behavior. The specific genes that influence …

The spectrum of germline predisposition in pediatric cancer continues to be realized. Here
we report 751 patients with solid tumors who underwent prospective matched tumor–normal …